Key result
Elevated Lp(a) linked to ~14% higher subsequent MACE risk in recurrent ASCVD.
Why the study?
Does elevated Lp(a) increase the risk of future major adverse cardiovascular events in patients with recurrent ASCVD?
Cohort (n=4,528)
Yes
Does elevated Lp(a) increase the risk of future major adverse cardiovascular events in patients with recurrent ASCVD?
Hazard Ratio: 1.14 (95% CI 1.03–1.26)
Absolute Event Rate: 37.7% vs 32.5%
p-value: p=0.012
No takes yet. Share an insight, caveat, or question.
Elevated Lp(a) ≥150 nmol/L is associated with a significantly increased risk and cumulative burden of subsequent MACE in patients with recurrent ASCVD, highlighting the need for targeted secondary prevention in this high-risk group.
Byrne et al. (2025) conducted a cohort in recurrent ASCVD (n=4,528). Elevated lipoprotein(a) (≥150 nmol/L) vs. Lp(a) <65 nmol/L was evaluated on subsequent MACE (MI, ischemic stroke, coronary revascularization, and all-cause death) (HR 1.14, 95% CI 1.03-1.26, p=0.012). In patients with recurrent ASCVD, elevated Lp(a) ≥150 nmol/L was associated with a higher risk of subsequent MACE compared to <65 nmol/L (37.7% vs 32.5%; HR 1.14; 95% CI 1.03-1.26; p=0.012).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: